Login / Signup

The healthy female microbiome across body sites: effect of hormonal contraceptives and the menstrual cycle.

Maria Christine KrogLuisa Warchavchik HugerthEmma FranssonZahra BashirAnders Nyboe AndersenGabriella EdfeldtLars EngstrandIna Schuppe-KoistinenHenriette Svarre Nielsen
Published in: Human reproduction (Oxford, England) (2022)
This work was partly funded by the Ferring Pharmaceuticals through a research collaboration with The Centre for Translational Microbiome Research (CTMR) at the Karolinska Institutet (L.W.H., E.F., G.E. and I.S.-K.). Ferring Pharmaceuticals also funded the infrastructure to obtain the clinical samples at Copenhagen University Hospital ([#MiHSN01], M.C.K., Z.B., and H.S.N.). This work was also supported by funding from Rigshospitalet's Research Funds ([#E-22614-01 and #E-22614-02] to M.C.K.) and Oda and Hans Svenningsen's Foundation ([#F-22614-08] to H.S.N.). M.C.K., L.W.H., E.F., Z.B., G.E., L.E., I.S.-K. and H.S.N., are partially funded by Ferring Pharmaceuticals, which also provided funds for the collection and processing of the samples analysed in this study. H.S.N.'s research is further supported by Freya Biosciences and the BioInnovation Institute. H.S.N. has received honoraria from Ferring Pharmaceuticals, Merck A/S, Astra-Zeneca, Cook Medical and Ibsa Nordic. A.N.A. reports no competing interests.
Keyphrases
  • healthcare
  • type diabetes
  • metabolic syndrome
  • skeletal muscle
  • adverse drug